Texan Allergy acquired Adair Allergy, expanding its services in allergy, asthma and clinical immunology care.

AcquirerTargetValueTypeClose DateAnnouncement DateBuy-side AdvisorsSell-side AdvisorsLegal (Buy)Legal (Sell)
Texan AllergyAdair AllergyUndisclosedAcquisition2026-07-09Not DisclosedNot DisclosedNot DisclosedMcGuireWoodsNot Disclosed

The deal, which closed on July 9, 2026, is aimed at bolstering Texan Allergy's presence in the allergy and asthma care market.

Deal Mechanics

Texan Allergy did not disclose financial details of the transaction but the law firm McGuireWoods represented the acquirer. No information was provided on sell-side advisors or financial terms such as key deal multiples or earn-out provisions.

Strategic Rationale

The acquisition is part of Texan Allergy's strategic plan to grow its service offerings and geographic reach in allergy, asthma, and clinical immunology care. Adair Allergy's expertise complements Texan Allergy's existing portfolio by adding new treatments and technologies.

Financial Context

While specific financial figures were not released, the healthcare sector has seen a steady increase in M&A activity as companies seek to consolidate market positions and expand service offerings. This acquisition aligns with broader trends of consolidation within the allergy treatment space.

Advisors

Texan Allergy was advised by McGuireWoods.